Abstract:Background: Geriatric depression with subjective memory complaints increases the risk for Alzheimer's Disease. Memantine, a neuroprotective drug, can improve depression and help prevent cognitive decline. In our 6-months clinical trial, escitalopram/memantine (ESC/MEM) improved mood and cognition compared to escitalopram/placebo treatment (ESC/PBO; NCT01902004). In this report, we investigated whether baseline brain white matter integrity in fronto-limbic-striatal tracts can predict clinical outcomes using fractional anisotropy (FA).Methods: Thirty-eight older depressed adults (mean age = 70.6, SD = 7.2) were randomized to ESC/MEM or ESC/PBO and underwent diffusion-weighted imaging (DWI) at 3 Tesla at baseline. Mood was assessed using the Hamilton Depression Rating Scale (HAMD), apathy using the Apathy Evaluation Scale (AES) and anxiety using the Hamilton Anxiety Scale (HAMA) at baseline and 6-months follow-up. FA was extracted from seven tracts of interest (six in each hemisphere and one commissural tract) associated with geriatric depression. Non-parametric General Linear Models were used to examine group differences in the association between FA and symptom improvement, controlling for age, sex, baseline symptom scores and scanner model, correcting for false discovery rate (FDR). Post-hoc tests further investigated group differences in axial, mean and radial diffusivity (AD, MD, and RD, respectively). Lastly, we performed an exploratory whole-brain model to test whether FA might be related to treatment response with memantine.Results: There were no differences in remission rates or HAMD change between groups. In bilateral anterior and posterior internal capsule tracts and bilateral inferior and right superior fronto-occipital (IFO and SFO) fasciculus, higher FA was associated with larger improvements in depressive symptoms for ESC/MEM, but not ESC/PBO, correcting for FDR. Lower MD in the left IFO and RD in the right anterior internal capsule were associated with improved treatment responses. We found no significant associations in the whole-brain analysis.Limitations: Included small sample size and high dropout.Conclusions: Higher baseline FA and lower RD and MD in hypothesized fronto-limbic-striatal tracts predicted greater improvement in mood and anxiety with ESC/MEM compared to ESC/PBO in geriatric depression. FA as a biomarker for white matter integrity may serve as a predictor of treatment response but requires confirmation in larger future studies.

Regional White Matter Integrity Predicts Treatment Response to Escitalopram and Memantine in Geriatric Depression: A Pilot Study

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression

Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge

Brain Microstructural Abnormalities Revealed by Diffusion Tensor Images in Patients with Treatment-Resistant Depression Compared with Major Depressive Disorder Before Treatment

Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study

Mapping the effect of escitalopram treatment on amplitude of low-frequency fluctuations in patients with depression: a resting-state fMRI study

Frontal-striatal tract integrity and depression in older adults with and without multiple sclerosis

Contribution of resting-state functional connectivity of the subgenual anterior cingulate to prediction of antidepressant efficacy in patients with major depressive disorder

Cerebral Volume Measurements and Subcortical White Matter Lesions and Short‐term Treatment Response in Late Life Depression

Association between change in brain gray matter volume, cognition, and depression severity: Pre- and post- antidepressant pharmacotherapy for late-life depression

Stability of frontal alpha asymmetry in depressed patients during antidepressant treatment

Effects of Memantine on Clinical Ratings, Fluorodeoxyglucose Positron Emission Tomography Measurements, and Cerebrospinal Fluid Assays in Patients with Moderate to Severe Alzheimer Dementia A 24-Week, Randomized, Clinical Trial

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder

Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder

Neural basis of the association between depressive symptoms and memory deficits in nondemented subjects: resting-state fMRI study.

Differential Effects of Antidepressant Treatment on Long-Range and Short-Range Functional Connectivity Strength in Patients with Major Depressive Disorder

Effects of Memantine on Maintaining White Matter Integrity in Alzheimer's Disease Patients with Agitation

Functional Connectivity of the Hippocampus in Predicting Early Antidepressant Efficacy in Patients with Major Depressive Disorder.